Fresenius SE & Co AI Stock Analysis
Fresenius SE & Co (FREA) AI Stock Analysis
Fresenius SE & Co
(Frankfurt:FREA)
No summary available
Fresenius SE & Co (FREA) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 133.60B
- Dividend Yield
- 1.93%
- Average Volume (3M)
- 185
- Price to Earnings (P/E)
- 19.1
- Beta (1Y)
- 1.04
- Revenue Growth
- 6.52%
- EPS Growth
- 35.52%
- Country
- Germany
- Employees
- 178,394
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Care Facilities
Fresenius SE & Co Business Overview & Revenue Model
Company Description
Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius...
Fresenius SE & Co Earnings Call Summary
The call was strongly positive, with broad-based organic growth, double-digit earnings growth, higher margins, improved cash generation, stronger returns, maintained leverage and raised full-year guidance. Fresenius also reported significant progress in biopharma, MedTech, Nutrition, hospital operations and digital health. The main challenges were Tyenne supply constraints and formulary changes, Nutrition-related supply issues in China, Pharma pricing and volume pressure, Melrose Park remediation, higher planned R&D investment and weaker Q4 phasing at Helios. These issues were explicitly discussed but did not outweigh the operational improvements and upgraded outlook.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Fresenius now expects full-year core EPS growth in the upper half of its 10% to 15% guidance range at constant currency, group EBIT margin above 11.5%, full-year interest expense below EUR 300 million, and a tax rate between 24% to 25%; if exchange rates remain at the spot rate of 30th September, it expects no material impact on reported revenue, EBIT or net income for the full year. Kabi’s full-year EBIT margin indication remains 16.5% to 17%, its structural growth band remains applicable, and Nutrition is expected to have an improved growth trajectory for the fourth quarter; Helios overall as a segment is expected to deliver EBIT growth in 2027. The 2030 ambition to double biopharma revenue at an EBIT margin of around 20% remains unchanged, while the self-imposed leverage corridor of 2.5 to 3x remains unchanged.
Fresenius SE & Co Peers Comparison
Overall Rating
THC87Outperform
OPCH72Outperform
FMS66Neutral
HCA64Neutral
DVA62Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 87Outperform | $22.76B | 8.24 | 60.60% | ― | 6.23% | 136.09% | |
| 72Outperform | $4.74B | 22.77 | 16.36% | ― | 4.01% | 9.94% | |
| 66Neutral | $11.75B | 13.41 | 6.34% | 3.92% | 4.27% | 26.14% | |
| 64Neutral | $104.25B | 16.49 | -100.45% | 0.61% | 5.82% | 16.59% | |
| 62Neutral | $10.98B | 13.40 | -133.21% | ― | 6.38% | 36.05% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:FREA | Fresenius Se | 13.20 | 1.43 | 12.12% | |
| OPCH | Option Care Health Inc | 31.65 | 3.54 | 12.59% | |
| DVA | DaVita Inc. | 174.56 | 57.29 | 48.85% | |
| FMS | Fresenius Medical Care | 22.03 | -0.36 | -1.63% | |
| HCA | Hca Healthcare | 499.05 | 25.19 | 5.32% | |
| THC | Tenet Healthcare Corp. | 286.03 | 93.63 | 48.66% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
